Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macugen Corneal Endothelium Safety Study
NCT01573572Phase 4Completed
- Sponsor
- Bausch + Lomb
- Start
- Apr 2010
- Primary completion
- Nov 2019
- Modality
- Antisense DNA, RNA Aptamers, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
A Phase 4 trial of pegaptanib sodium in age-related macular degeneration (AMD), retinal vein occlusion (RVO), diabetic macular edema (DME), sponsored by Bausch + Lomb. Started Apr 2010; status: completed.
02
Drugs
pegaptanib sodium
03
Conditions
age-related macular degeneration (AMD)retinal vein occlusion (RVO)diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT01573572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01573572.